Quest for the right Drug
לוריוון LORIVAN (LORAZEPAM)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects Adverse reactions, when they occur, are usually observed at the beginning of therapy and generally decrease in severity or disappear with continued use or upon decreasing the dose. System Organ Very Common Common Uncommon Frequency Class ≥ 1/10 ≥ 1/100 to < ≥ 1/1,000 to not known 1/10 < 1/100 (cannot be estimated from the available data) Blood and Thrombocytopenia, lymphatic agranulocytosis, system disorders pancytopenia Immune system Hypersensitivity disorders reactions, anaphylactic/oid reactions Endocrine SIADH disorders Metabolism and Hyponatremia nutrition disorders Psychiatric Confusion, Change in libido, Disinhibition, euphoria, disorders depression, decreased suicidal unmasking of orgasm ideation/attempt, depression paradoxical reactions, including anxiety, agitation, excitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, hallucinations, drug abuse, drug dependence Nervous system Sedation, Ataxia, dizziness Extrapyramidal disorders± drowsiness symptoms, tremor, dysarthria/slurred speech, headache, convulsions/seizures, amnesia, coma, impaired attention/concentration, balance disorder Eye disorders Visual disturbances (including diplopia and blurred vision) Ear and labyrinth Vertigo disorders Vascular Hypotension, lowering disorders in blood pressure Respiratory, Respiratory thoracic and depressionβ, apnea, mediastinal worsening of sleep disorders apnea, worsening of obstructive pulmonary disease Gastrointestinal Nausea Constipation disorders Hepatobiliary Jaundice disorders Skin and Angioedema, allergic subcutaneous skin reactions, alopecia tissue disorders Musculoskeletal Muscle and weakness connective tissue disorders Reproductive Impotence system and breast disorders General disorders Fatigue Asthenia Hypothermia, drug and withdrawal syndrome administration site conditions Investigations Increase in bilirubin, increase in liver transaminases, increase in alkaline phosphatase ± Benzodiazepine effects on the CNS are dose-dependent, with more severe CNS depression occurring with high doses. β The extent of respiratory depression with benzodiazepines is dose dependent, with more severe depression occurring with high doses. Pre-existing depression may emerge during benzodiazepine use. Transient anterograde amnesia or memory impairment may occur using therapeutic doses, the risk increasing at higher doses (see section 4.4) Paradoxical reactions such as restlessness, agitation, irritability, aggressiveness, delusion, rage, nightmares, hallucinations, psychoses, and inappropriate behaviour have been occasionally reported during benzodiazepine use. Such reactions may be more likely to occur in children and the elderly (see section 4.4). Use (even at therapeutic doses) may lead to physical or psychological dependence and discontinuation of treatment may result in withdrawal reactions or rebound phenomena (see section 4.4). Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
Anxiety & tension
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף